CN117649247A - Drug tracing method and device - Google Patents
Drug tracing method and device Download PDFInfo
- Publication number
- CN117649247A CN117649247A CN202311585588.7A CN202311585588A CN117649247A CN 117649247 A CN117649247 A CN 117649247A CN 202311585588 A CN202311585588 A CN 202311585588A CN 117649247 A CN117649247 A CN 117649247A
- Authority
- CN
- China
- Prior art keywords
- drug
- related information
- blockchain
- medicine
- authentication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 260
- 229940079593 drug Drugs 0.000 title claims abstract description 197
- 238000000034 method Methods 0.000 title claims abstract description 63
- 230000004044 response Effects 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims description 58
- 238000003860 storage Methods 0.000 claims description 13
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 238000004590 computer program Methods 0.000 description 10
- 238000010586 diagram Methods 0.000 description 5
- 238000004891 communication Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000013500 data storage Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003962 counterfeit drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004984 smart glass Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/018—Certifying business or products
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/24—Querying
- G06F16/242—Query formulation
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/25—Integrating or interfacing systems involving database management systems
- G06F16/252—Integrating or interfacing systems involving database management systems between a Database Management System and a front-end application
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K7/00—Methods or arrangements for sensing record carriers, e.g. for reading patterns
- G06K7/10—Methods or arrangements for sensing record carriers, e.g. for reading patterns by electromagnetic radiation, e.g. optical sensing; by corpuscular radiation
- G06K7/14—Methods or arrangements for sensing record carriers, e.g. for reading patterns by electromagnetic radiation, e.g. optical sensing; by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
- G06K7/1404—Methods for optical code recognition
- G06K7/1408—Methods for optical code recognition the method being specifically adapted for the type of code
- G06K7/1417—2D bar codes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P90/00—Enabling technologies with a potential contribution to greenhouse gas [GHG] emissions mitigation
- Y02P90/30—Computing systems specially adapted for manufacturing
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Databases & Information Systems (AREA)
- General Physics & Mathematics (AREA)
- Business, Economics & Management (AREA)
- Data Mining & Analysis (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Accounting & Taxation (AREA)
- Electromagnetism (AREA)
- General Health & Medical Sciences (AREA)
- Computational Linguistics (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Mathematical Physics (AREA)
- Entrepreneurship & Innovation (AREA)
- Health & Medical Sciences (AREA)
- Development Economics (AREA)
- Economics (AREA)
- Finance (AREA)
- Marketing (AREA)
- Strategic Management (AREA)
- General Business, Economics & Management (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
The embodiment of the specification provides a drug traceability method and device, wherein the drug traceability method comprises the following steps: acquiring medicine related information, and storing the medicine related information into a blockchain; determining access rights based on the user access instructions in response to the user access instructions; acquiring drug related information from the blockchain based on the access rights; and carrying out drug tracing based on the drug related information. Storing the drug related information to a blockchain by acquiring the drug related information; determining access rights based on the user access instructions in response to the user access instructions; acquiring drug related information from the blockchain based on the access rights; drug tracing is performed based on drug related information, so that accuracy and integrity of drug information when recorded to a blockchain are ensured, and false information is prevented from being recorded.
Description
Technical Field
The embodiment of the specification relates to the technical field of blockchain, in particular to a drug traceability method.
Background
Current methods of tracking the drug supply chain include bar code and RFID technology, digital authentication and digital signature, and database and centralised systems. Wherein the flow direction of the drug in the supply chain can be tracked by attaching a bar code or RFID (Radio Frequency Identification) tag to the drug package. However, these methods are easy to tamper with, and cannot provide data authenticity assurance. In addition, digital authentication and digital signature techniques are used to ensure the integrity and origin of data, but these methods do not address the centralization of data storage and are susceptible to data tampering or man-in-the-middle attacks. Some medical institutions may use databases to record medication information, but such centralized data stores present a single point of failure and risk of data leakage.
Thus, a better solution is needed.
Disclosure of Invention
In view of this, the present description embodiments provide a drug traceability method. One or more embodiments of the present specification relate to a drug traceability device, a computing apparatus, a computer-readable storage medium and a computer program, which solve the technical drawbacks existing in the prior art.
According to a first aspect of embodiments of the present disclosure, there is provided a drug traceability method, including:
acquiring medicine related information, and storing the medicine related information into a blockchain;
determining access rights based on the user access instructions in response to the user access instructions;
acquiring drug related information from the blockchain based on the access rights;
and carrying out drug tracing based on the drug related information.
In one possible implementation, acquiring drug related information, storing the drug related information to a blockchain, includes:
obtaining the name, production batch, manufacturer and date of production of the medicine;
drug names, production lots, manufacturers, and production dates are stored to the blockchain.
In one possible implementation, in response to a user access instruction, determining access rights based on the user access instruction includes:
responding to a user access instruction, and acquiring user identity information from the user access instruction;
matching in a user information database based on the user identity information, and determining a matching result;
and determining the access right based on the matching result.
In one possible implementation, obtaining medication-related information from a blockchain based on access rights includes:
under the condition that the access authority is allowed to access, acquiring target drug identification parameters;
drug related information is obtained from the blockchain based on the drug identification parameters.
In one possible implementation, performing drug tracing based on drug related information includes:
determining an authentication medicine name, an authentication production lot, an authentication manufacturer and an authentication production date based on the medicine-related information;
determining the name, the current production batch, the current manufacturer and the current production date of the current medicine;
performing name authentication based on the authenticated medicine name and the current medicine name, and determining a name tracing result;
performing batch authentication based on the authenticated production batch and the current production batch, and determining a batch tracing result;
based on authentication manufacturers and current manufacturers, manufacturer authentication is carried out, and a manufacturer tracing result is determined;
and carrying out date authentication based on the authentication production date and the current production date, and determining a date tracing result.
In one possible implementation, the method further includes:
and under the condition that the name tracing result, the batch tracing result, the manufacturer tracing result and the date tracing result are abnormal, recording the current medicine in an abnormal list.
In one possible implementation, after obtaining the drug related information from the blockchain based on the access rights, the method further includes:
determining a drug usage method and a drug usage dose based on the drug-related information;
generating a drug usage record based on the drug usage method and the drug usage dose;
drug usage records are stored to the blockchain.
According to a second aspect of embodiments of the present specification, there is provided a drug traceability device comprising:
the information storage module is configured to acquire medicine related information and store the medicine related information into the blockchain;
a permission determination module configured to determine access permissions based on the user access instructions in response to the user access instructions;
an information acquisition module configured to acquire drug related information from the blockchain based on the access rights;
and the medicine tracing module is configured to trace medicine based on the medicine related information.
According to a third aspect of embodiments of the present specification, there is provided a computing device comprising:
a memory and a processor;
the memory is configured to store computer-executable instructions, and the processor is configured to execute the computer-executable instructions, which when executed by the processor, implement the steps of the drug traceability method described above.
According to a fourth aspect of embodiments of the present specification, there is provided a computer readable storage medium storing computer executable instructions which, when executed by a processor, implement the steps of the drug traceability method described above.
According to a fifth aspect of embodiments of the present specification, there is provided a computer program, wherein the computer program, when executed in a computer, causes the computer to perform the steps of the drug traceability method described above.
The embodiment of the specification provides a drug traceability method and device, wherein the drug traceability method comprises the following steps: acquiring medicine related information, and storing the medicine related information into a blockchain; determining access rights based on the user access instructions in response to the user access instructions; acquiring drug related information from the blockchain based on the access rights; and carrying out drug tracing based on the drug related information. Storing the drug related information to a blockchain by acquiring the drug related information; determining access rights based on the user access instructions in response to the user access instructions; acquiring drug related information from the blockchain based on the access rights; drug tracing is performed based on drug related information, so that accuracy and integrity of drug information when recorded to a blockchain are ensured, and false information is prevented from being recorded.
Drawings
Fig. 1 is a schematic view of a scenario of a drug traceability method according to an embodiment of the present disclosure;
FIG. 2 is a flow chart of a drug traceability method according to one embodiment of the present disclosure;
fig. 3 is a schematic structural diagram of a drug traceability device according to an embodiment of the present disclosure;
FIG. 4 is a block diagram of a computing device provided in one embodiment of the present description.
Detailed Description
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present description. This description may be embodied in many other forms than described herein and similarly generalized by those skilled in the art to whom this disclosure pertains without departing from the spirit of the disclosure and, therefore, this disclosure is not limited by the specific implementations disclosed below.
The terminology used in the one or more embodiments of the specification is for the purpose of describing particular embodiments only and is not intended to be limiting of the one or more embodiments of the specification. As used in this specification, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It should also be understood that the term "and/or" as used in one or more embodiments of the present specification refers to and encompasses any or all possible combinations of one or more of the associated listed items.
It should be understood that, although the terms first, second, etc. may be used in one or more embodiments of this specification to describe various information, these information should not be limited by these terms. These terms are only used to distinguish one type of information from another. For example, a first may also be referred to as a second, and similarly, a second may also be referred to as a first, without departing from the scope of one or more embodiments of the present description. The word "if" as used herein may be interpreted as "at … …" or "at … …" or "responsive to a determination", depending on the context.
In the present specification, a drug traceability method is provided, and the present specification relates to a drug traceability device, a computing apparatus, and a computer-readable storage medium, and is described in detail in the following embodiments one by one.
Referring to fig. 1, fig. 1 is a schematic view of a scenario of a drug traceability method according to an embodiment of the present disclosure.
In the application scenario of fig. 1, computing device 101 may obtain drug related information, storing the drug related information to blockchain 102. The computing device 101 may then determine the access rights 103 based on the user access instructions in response to the user access instructions. Thereafter, the computing device 101 may obtain the medication-related information 104 from the blockchain 102 based on the access rights 103. Finally, the computing device 101 may perform drug traceability based on the drug-related information 104, as indicated by reference numeral 105.
The computing device 101 may be hardware or software. When the computing device 101 is hardware, it may be implemented as a distributed cluster of multiple servers or terminal devices, or as a single server or single terminal device. When the computing device 101 is embodied as software, it may be installed in the hardware devices listed above. It may be implemented as a plurality of software or software modules, for example, for providing distributed services, or as a single software or software module. The present invention is not particularly limited herein.
Referring to fig. 2, fig. 2 shows a flowchart of a drug tracing method according to an embodiment of the present disclosure, which specifically includes the following steps.
Step 201: drug related information is obtained and stored in the blockchain.
In one possible implementation, acquiring drug related information, storing the drug related information to a blockchain, includes: obtaining the name, production batch, manufacturer and date of production of the medicine; drug names, production lots, manufacturers, and production dates are stored to the blockchain.
In practical applications, blockchain technology can ensure the authenticity and non-tamper-ability of drug information. The production, circulation and sales information of the medicines are recorded on the blockchain, and anyone can trace the source and the flow direction of the medicines, so that the problem of counterfeit medicines is effectively reduced. At the time of each batch of medicine production, related information such as medicine name, production lot, manufacturer, date of production, etc. is recorded on the blockchain. Once written to the blockchain, this information is not modifiable, ensuring the non-tamperability and trustworthiness of the data.
For example, the medicine name a is acquired, the production lot is M1, the manufacturer is N pharmaceutical company, and the production date is T1. The drug name a, production lot M1, manufacturer N pharmaceutical company, production date T1 is stored on the blockchain.
Further, information from each step is also recorded on the blockchain during the course of drug delivery from production to delivery. Including drug shipping information, dealer information, retailer information, etc. In this way, anyone can trace back the flow direction and storage condition of the drug.
Step 202: in response to the user access instruction, an access right is determined based on the user access instruction.
In one possible implementation, in response to a user access instruction, determining access rights based on the user access instruction includes: responding to a user access instruction, and acquiring user identity information from the user access instruction; matching in a user information database based on the user identity information, and determining a matching result; and determining the access right based on the matching result.
In practical application, the traditional data storage and exchange mode is easy to be threatened by data leakage and tampering. The blockchain protects the privacy of data by using a cryptography technology, ensures the security of the data through a consensus mechanism, and only authorized users can access the data.
Step 203: drug related information is obtained from the blockchain based on the access rights.
In one possible implementation, obtaining medication-related information from a blockchain based on access rights includes: under the condition that the access authority is allowed to access, acquiring target drug identification parameters; drug related information is obtained from the blockchain based on the drug identification parameters.
In practical applications, users with access rights can access the data in the blockchain, and the identities of the patient, doctor, etc. can access the data. And the treatment data of the patient can be stored on the blockchain, and the treatment data of the patient and the data of the treatment medicine are associated, so that the privacy of the data is ensured, and the safety of the data is improved.
Step 204: and carrying out drug tracing based on the drug related information.
In one possible implementation, performing drug tracing based on drug related information includes: determining an authentication medicine name, an authentication production lot, an authentication manufacturer and an authentication production date based on the medicine-related information; determining the name, the current production batch, the current manufacturer and the current production date of the current medicine; performing name authentication based on the authenticated medicine name and the current medicine name, and determining a name tracing result; performing batch authentication based on the authenticated production batch and the current production batch, and determining a batch tracing result; based on authentication manufacturers and current manufacturers, manufacturer authentication is carried out, and a manufacturer tracing result is determined; and carrying out date authentication based on the authentication production date and the current production date, and determining a date tracing result.
In practice, the patient may access the drug information on the blockchain by scanning a two-dimensional code on the drug package or using a mobile application. In this way, the patient can ensure that the purchased medication is authentic and not falsely replaced. Blockchains can be used to verify compliance of a drug. Medical authorities and patients can confirm whether the medication meets regulatory standards and has not been tampered with by accessing blockchain data.
Furthermore, if a batch of medicines is found to be problematic, a specific production batch can be traced to quickly through the blockchain, so that recall is performed or circulation is restricted, and the medication safety of patients is ensured.
In conclusion, the drug traceability and anti-counterfeiting based on the blockchain can greatly improve the transparency and the credibility of a drug supply chain, and has positive influence on the overall safety and the patient rights and interests protection of the pharmaceutical industry. However, implementing such a system requires cooperation of the respective parties and adoption of standardized data recording methods, while also taking into consideration privacy protection and the like.
In one possible implementation, the method further includes: and under the condition that the name tracing result, the batch tracing result, the manufacturer tracing result and the date tracing result are abnormal, recording the current medicine in an abnormal list.
In practical application, the abnormal medicines can be recorded, so that the medicines with problems are monitored and identified, the medicines can be locked through the abnormal list, and the medicines in the abnormal list are removed under the condition of next medicine opening.
In one possible implementation, after obtaining the drug related information from the blockchain based on the access rights, the method further includes: determining a drug usage method and a drug usage dose based on the drug-related information; generating a drug usage record based on the drug usage method and the drug usage dose; drug usage records are stored to the blockchain.
In practical application, the using method of the medicine and the using dosage of the medicine can be recorded on the blockchain, under the condition that a doctor needs to prescribe medicine to a patient, the using method of the medicine and the using dosage of the medicine can be directly obtained, the medicine using record is generated for the patient, and the medicine using record is stored on the blockchain, so that the using safety of the medicine can be ensured, the using record of the patient can be stored, the medical record of the patient can be generated later according to the using record, and the medical record of the patient can be obtained by checking the electronic medical record under the condition that other doctors diagnose.
The embodiment of the specification provides a drug traceability method and device, wherein the drug traceability method comprises the following steps: acquiring medicine related information, and storing the medicine related information into a blockchain; determining access rights based on the user access instructions in response to the user access instructions; acquiring drug related information from the blockchain based on the access rights; and carrying out drug tracing based on the drug related information. Storing the drug related information to a blockchain by acquiring the drug related information; determining access rights based on the user access instructions in response to the user access instructions; acquiring drug related information from the blockchain based on the access rights; drug tracing is performed based on drug related information, so that accuracy and integrity of drug information when recorded to a blockchain are ensured, and false information is prevented from being recorded.
Corresponding to the method embodiment, the present disclosure further provides a drug traceability device embodiment, and fig. 3 shows a schematic structural diagram of the drug traceability device according to one embodiment of the present disclosure. As shown in fig. 3, the apparatus includes:
an information storage module 301 configured to acquire medicine-related information, store the medicine-related information to the blockchain;
a rights determination module 302 configured to determine access rights based on the user access instructions in response to the user access instructions;
an information acquisition module 303 configured to acquire drug related information from the blockchain based on access rights;
the medication tracing module 304 is configured to trace medication based on medication related information.
In one possible implementation, the information storage module 301 is further configured to: acquiring drug related information, storing the drug related information to a blockchain, comprising: obtaining the name, production batch, manufacturer and date of production of the medicine; drug names, production lots, manufacturers, and production dates are stored to the blockchain.
In one possible implementation, the rights determination module 302 is further configured to: in response to the user access instruction, determining access rights based on the user access instruction includes: responding to a user access instruction, and acquiring user identity information from the user access instruction; matching in a user information database based on the user identity information, and determining a matching result; and determining the access right based on the matching result.
In one possible implementation, the information acquisition module 303 is further configured to: obtaining medication-related information from a blockchain based on access rights, including: under the condition that the access authority is allowed to access, acquiring target drug identification parameters; drug related information is obtained from the blockchain based on the drug identification parameters.
In one possible implementation, the drug traceability module 304 is further configured to: drug traceability is performed based on drug related information, including: determining an authentication medicine name, an authentication production lot, an authentication manufacturer and an authentication production date based on the medicine-related information; determining the name, the current production batch, the current manufacturer and the current production date of the current medicine; performing name authentication based on the authenticated medicine name and the current medicine name, and determining a name tracing result; performing batch authentication based on the authenticated production batch and the current production batch, and determining a batch tracing result; based on authentication manufacturers and current manufacturers, manufacturer authentication is carried out, and a manufacturer tracing result is determined; and carrying out date authentication based on the authentication production date and the current production date, and determining a date tracing result.
In one possible implementation, the drug traceability module 304 is further configured to: and under the condition that the name tracing result, the batch tracing result, the manufacturer tracing result and the date tracing result are abnormal, recording the current medicine in an abnormal list.
In one possible implementation, the drug traceability module 304 is further configured to: determining a drug usage method and a drug usage dose based on the drug-related information; generating a drug usage record based on the drug usage method and the drug usage dose; drug usage records are stored to the blockchain.
The embodiment of the specification provides a drug traceability method and device, wherein the drug traceability method comprises the following steps: acquiring medicine related information, and storing the medicine related information into a blockchain; determining access rights based on the user access instructions in response to the user access instructions; acquiring drug related information from the blockchain based on the access rights; and carrying out drug tracing based on the drug related information. Storing the drug related information to a blockchain by acquiring the drug related information; determining access rights based on the user access instructions in response to the user access instructions; acquiring drug related information from the blockchain based on the access rights; drug tracing is performed based on drug related information, so that accuracy and integrity of drug information when recorded to a blockchain are ensured, and false information is prevented from being recorded.
The above is a schematic scheme of a drug traceability device of this embodiment. It should be noted that, the technical solution of the drug tracing device and the technical solution of the drug tracing method belong to the same concept, and details of the technical solution of the drug tracing device which are not described in detail can be referred to the description of the technical solution of the drug tracing method.
Fig. 4 illustrates a block diagram of a computing device 400 provided in accordance with one embodiment of the present description. The components of the computing device 400 include, but are not limited to, a memory 410 and a processor 420. Processor 420 is coupled to memory 410 via bus 430 and database 450 is used to hold data.
Computing device 400 also includes access device 440, access device 440 enabling computing device 400 to communicate via one or more networks 460. Examples of such networks include public switched telephone networks (PSTN, public Switched Telephone Network), local area networks (LAN, local Area Network), wide area networks (WAN, wide Area Network), personal area networks (PAN, personal Area Network), or combinations of communication networks such as the internet. The access device 440 may include one or more of any type of network interface, wired or wireless, such as a network interface card (NIC, network interface controller), such as an IEEE802.11 wireless local area network (WLAN, wireless Local Area Network) wireless interface, a worldwide interoperability for microwave access (Wi-MAX, worldwide Interoperability for Microwave Access) interface, an ethernet interface, a universal serial bus (USB, universal Serial Bus) interface, a cellular network interface, a bluetooth interface, near field communication (NFC, near Field Communication).
In one embodiment of the present description, the above-described components of computing device 400, as well as other components not shown in FIG. 4, may also be connected to each other, such as by a bus. It should be understood that the block diagram of the computing device shown in FIG. 4 is for exemplary purposes only and is not intended to limit the scope of the present description. Those skilled in the art may add or replace other components as desired.
Computing device 400 may be any type of stationary or mobile computing device, including a mobile computer or mobile computing device (e.g., tablet, personal digital assistant, laptop, notebook, netbook, etc.), mobile phone (e.g., smart phone), wearable computing device (e.g., smart watch, smart glasses, etc.), or other type of mobile device, or a stationary computing device such as a desktop computer or personal computer (PC, personal Computer). Computing device 400 may also be a mobile or stationary server.
The processor 420 is configured to execute computer-executable instructions that, when executed by the processor, implement the steps of the drug traceability method described above. The foregoing is a schematic illustration of a computing device of this embodiment. It should be noted that, the technical solution of the computing device and the technical solution of the drug tracing method belong to the same concept, and details of the technical solution of the computing device, which are not described in detail, can be referred to the description of the technical solution of the drug tracing method.
An embodiment of the present disclosure further provides a computer-readable storage medium storing computer-executable instructions that, when executed by a processor, implement the steps of the drug traceability method described above.
The above is an exemplary version of a computer-readable storage medium of the present embodiment. It should be noted that, the technical solution of the storage medium and the technical solution of the drug tracing method belong to the same concept, and details of the technical solution of the storage medium which are not described in detail can be referred to the description of the technical solution of the drug tracing method.
An embodiment of the present disclosure further provides a computer program, where the computer program when executed in a computer causes the computer to perform the steps of the drug traceability method described above.
The above is an exemplary version of a computer program of the present embodiment. It should be noted that, the technical solution of the computer program and the technical solution of the drug tracing method belong to the same conception, and details of the technical solution of the computer program which are not described in detail can be referred to the description of the technical solution of the drug tracing method.
The foregoing describes specific embodiments of the present disclosure. Other embodiments are within the scope of the following claims. In some cases, the actions or steps recited in the claims can be performed in a different order than in the embodiments and still achieve desirable results. In addition, the processes depicted in the accompanying figures do not necessarily require the particular order shown, or sequential order, to achieve desirable results. In some embodiments, multitasking and parallel processing are also possible or may be advantageous.
The computer instructions include computer program code that may be in source code form, object code form, executable file or some intermediate form, etc. The computer readable medium may include: any entity or device capable of carrying the computer program code, a recording medium, a U disk, a removable hard disk, a magnetic disk, an optical disk, a computer Memory, a Read-Only Memory (ROM), a random access Memory (RAM, random Access Memory), an electrical carrier signal, a telecommunications signal, a software distribution medium, and so forth. It should be noted that the computer readable medium contains content that can be appropriately scaled according to the requirements of jurisdictions in which such content is subject to legislation and patent practice, such as in certain jurisdictions in which such content is subject to legislation and patent practice, the computer readable medium does not include electrical carrier signals and telecommunication signals.
It should be noted that, for simplicity of description, the foregoing method embodiments are all expressed as a series of combinations of actions, but it should be understood by those skilled in the art that the embodiments are not limited by the order of actions described, as some steps may be performed in other order or simultaneously according to the embodiments of the present disclosure. Further, those skilled in the art will appreciate that the embodiments described in the specification are all preferred embodiments, and that the acts and modules referred to are not necessarily all required for the embodiments described in the specification.
In the foregoing embodiments, the descriptions of the embodiments are emphasized, and for parts of one embodiment that are not described in detail, reference may be made to the related descriptions of other embodiments.
The preferred embodiments of the present specification disclosed above are merely used to help clarify the present specification. Alternative embodiments are not intended to be exhaustive or to limit the invention to the precise form disclosed. Obviously, many modifications and variations are possible in light of the teaching of the embodiments. The embodiments were chosen and described in order to best explain the principles of the embodiments and the practical application, to thereby enable others skilled in the art to best understand and utilize the invention. This specification is to be limited only by the claims and the full scope and equivalents thereof.
Claims (10)
1. A method of drug traceability, comprising:
acquiring medicine related information, and storing the medicine related information into a blockchain;
determining the access rights based on a user access instruction in response to the user access instruction;
acquiring the drug related information from the blockchain based on the access rights;
and carrying out drug tracing based on the drug related information.
2. The method of claim 1, wherein the obtaining the medication-related information, storing the medication-related information in a blockchain, comprises:
obtaining the name, production batch, manufacturer and date of production of the medicine;
storing the drug name, the production lot, the manufacturer, and the production date to a blockchain.
3. The method of claim 1, wherein the determining the access rights based on the user access instructions in response to the user access instructions comprises:
responding to a user access instruction, and acquiring user identity information from the user access instruction;
matching in a user information database based on the user identity information, and determining a matching result;
and determining the access right based on the matching result.
4. The method of claim 1, wherein the obtaining the drug related information from the blockchain based on the access rights comprises:
under the condition that the access authority is allowed to access, acquiring target drug identification parameters;
the drug related information is obtained from the blockchain based on the drug identification parameter.
5. The method of claim 1, wherein the performing drug tracing based on the drug-related information comprises:
determining an authentication medicine name, an authentication production lot, an authentication manufacturer and an authentication production date based on the medicine-related information;
determining the name, the current production batch, the current manufacturer and the current production date of the current medicine;
performing name authentication based on the authentication medicine name and the current medicine name, and determining a name tracing result;
performing batch authentication based on the authentication production batch and the current production batch, and determining a batch tracing result;
based on the authentication manufacturer and the current manufacturer, performing manufacturer authentication, and determining a manufacturer tracing result;
and carrying out date authentication based on the authentication production date and the current production date, and determining a date tracing result.
6. The method as recited in claim 5, further comprising:
and recording the current medicine in an abnormal list under the condition that the name tracing result, the batch tracing result, the manufacturer tracing result and the date tracing result are abnormal.
7. The method of claim 1, wherein after the obtaining the drug related information from the blockchain based on the access rights, further comprises:
determining a drug usage method and a drug usage dose based on the drug related information;
generating a drug usage record based on the drug usage method and the drug usage dose;
the drug usage record is stored to the blockchain.
8. A drug traceability device, comprising:
an information storage module configured to acquire drug related information, and store the drug related information to a blockchain;
a rights determination module configured to determine the access rights based on a user access instruction in response to the user access instruction;
an information acquisition module configured to acquire the drug related information from the blockchain based on the access rights;
and the medicine tracing module is configured to trace medicine based on the medicine related information.
9. A computing device, comprising:
a memory and a processor;
the memory is configured to store computer executable instructions, and the processor is configured to execute the computer executable instructions, which when executed by the processor, implement the steps of the medication trace method of any one of claims 1 to 7.
10. A computer readable storage medium storing computer executable instructions which when executed by a processor perform the steps of the drug traceability method of any of claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311585588.7A CN117649247A (en) | 2023-11-24 | 2023-11-24 | Drug tracing method and device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311585588.7A CN117649247A (en) | 2023-11-24 | 2023-11-24 | Drug tracing method and device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117649247A true CN117649247A (en) | 2024-03-05 |
Family
ID=90042681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311585588.7A Pending CN117649247A (en) | 2023-11-24 | 2023-11-24 | Drug tracing method and device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117649247A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109461008A (en) * | 2018-11-02 | 2019-03-12 | 北京赛腾标识系统股份公司 | Drug Administration method and system based on block chain |
| CN110930167A (en) * | 2019-11-21 | 2020-03-27 | 山东爱城市网信息技术有限公司 | Block chain-based medicine information recording method, equipment and medium |
| CN111008844A (en) * | 2019-11-21 | 2020-04-14 | 山东爱城市网信息技术有限公司 | Block chain-based drug tracing method, device and medium |
| CN112184268A (en) * | 2020-10-27 | 2021-01-05 | 广州市家庭医生在线信息有限公司 | Medicine traceability management method and system based on block chain technology |
| CN114119038A (en) * | 2021-08-23 | 2022-03-01 | 广州方舟信息科技有限公司 | Medicine tracing method, device and equipment based on block chain technology |
| CN114694778A (en) * | 2022-04-20 | 2022-07-01 | 上海信医科技有限公司 | Medical data asset method, system and storage medium based on block chain |
| CN116777476A (en) * | 2023-06-09 | 2023-09-19 | 云南财经大学 | Medicine credible tracing method based on public key searchable encryption |
-
2023
- 2023-11-24 CN CN202311585588.7A patent/CN117649247A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109461008A (en) * | 2018-11-02 | 2019-03-12 | 北京赛腾标识系统股份公司 | Drug Administration method and system based on block chain |
| CN110930167A (en) * | 2019-11-21 | 2020-03-27 | 山东爱城市网信息技术有限公司 | Block chain-based medicine information recording method, equipment and medium |
| CN111008844A (en) * | 2019-11-21 | 2020-04-14 | 山东爱城市网信息技术有限公司 | Block chain-based drug tracing method, device and medium |
| CN112184268A (en) * | 2020-10-27 | 2021-01-05 | 广州市家庭医生在线信息有限公司 | Medicine traceability management method and system based on block chain technology |
| CN114119038A (en) * | 2021-08-23 | 2022-03-01 | 广州方舟信息科技有限公司 | Medicine tracing method, device and equipment based on block chain technology |
| CN114694778A (en) * | 2022-04-20 | 2022-07-01 | 上海信医科技有限公司 | Medical data asset method, system and storage medium based on block chain |
| CN116777476A (en) * | 2023-06-09 | 2023-09-19 | 云南财经大学 | Medicine credible tracing method based on public key searchable encryption |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Musamih et al. | A blockchain-based approach for drug traceability in healthcare supply chain | |
| EP3819855A1 (en) | Cross-block chain interaction method and system, computer device, and storage medium | |
| US11562812B2 (en) | Computer implemented method for secure management of data generated in an EHR during an episode of care and a system therefor | |
| EP3227853A1 (en) | Cryptographic verification of provenance in a supply chain | |
| RU2660647C2 (en) | Method and system for product authentication | |
| US20170076065A1 (en) | System, device, and automated method for verification of medication integrity and chain of custody | |
| US20190272908A1 (en) | System and method for detecting pharmaceutical counterfeit and fraudulent prescription | |
| US20150213204A1 (en) | Dual smart card e-prescription system and method | |
| CN108665953A (en) | A kind of prescription executes method, apparatus, equipment and storage medium | |
| CN112184252A (en) | Commodity anti-counterfeiting tracing method based on block chain technology | |
| CN110766324A (en) | Medicine state monitoring method, device, equipment and storage medium | |
| CN106254366A (en) | For the identification processing method patrolled and examined, Apparatus and system | |
| EP4012974A1 (en) | Cryptographically verifiable, portable certificate | |
| Evans | Improving the transparency of the pharmaceutical supply chain through the adoption of quick response (QR) code, Internet of Things (IOT), and blockchain technology: One result: Ending the Opioid crisis | |
| Sarkar | Blockchain for combating pharmaceutical drug counterfeiting and cold chain distribution | |
| Emmanuel et al. | A Hybrid Framework of Blockchain and IoT Technology in the Pharmaceutical Industry: A Comprehensive Study | |
| EP3048821A1 (en) | User verification | |
| CN117649247A (en) | Drug tracing method and device | |
| CN108765615B (en) | Block chain-based card punching information storage method and system | |
| US20190355451A1 (en) | System, methods, and apparatuses for medication records tracking | |
| US11270541B2 (en) | Method and system for secure product delivery using cryptography | |
| Nalam | Systematic review of pharmaceutical drugs serialization | |
| Reno et al. | Hyperledger based private blockchain technology in pharmaceutical manufacturing industry for preventing substandard drug production | |
| Haider et al. | Cybersecurity of medical devices: Past, present, and future | |
| Tounsi et al. | Fine-grained privacy control for the RFID middleware of EPCglobal networks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |